Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 83


Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature.

Berger JS, Sallum RH, Katona B, Maya J, Ranganathan G, Xu Y, Mwamburi M.

Am Heart J. 2012 Aug;164(2):153-162.e5. doi: 10.1016/j.ahj.2012.04.001. Epub 2012 Jul 17. Review.


Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.

Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Fox KA, Granger CB, Jolly S, Rupprecht HJ, Widimsky P, Yusuf S; CURRENT-OASIS 7 Steering Committee.

Am Heart J. 2008 Dec;156(6):1080-1088.e1. doi: 10.1016/j.ahj.2008.07.026. Epub 2008 Nov 1.


A risk score to predict bleeding in patients with acute coronary syndromes.

Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G, Lansky AJ, Stone GW.

J Am Coll Cardiol. 2010 Jun 8;55(23):2556-66. doi: 10.1016/j.jacc.2009.09.076.


Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry.

Bangalore S, Cohen DJ, Kleiman NS, Regev-Beinart T, Rao SV, Pencina MJ, Mauri L; EVENT Registry Investigators, Boston, MA.

Circ Cardiovasc Interv. 2011 Oct 1;4(5):463-73. doi: 10.1161/CIRCINTERVENTIONS.111.961912. Epub 2011 Oct 4.


The association between prior use of aspirin and/or warfarin and the in-hospital management and outcomes in patients presenting with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE).

Amad H, Yan AT, Yan RT, Huynh T, Gore JM, Montalescot G, DeYoung JP, Gallo R, Rose B, Steg PG, Goodman SG; Canadian Global Registry of Acute Coronary Events (GRACE) Investigators.

Can J Cardiol. 2012 Jan-Feb;28(1):48-53. doi: 10.1016/j.cjca.2011.09.003. Epub 2011 Nov 23.


[Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome].

Kjaer J, Larsen CH, Poulsen TS, Møller JE, Mickley H.

Ugeskr Laeger. 2006 Sep 18;168(38):3209-14. Danish.


Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.

Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R.

Health Technol Assess. 2004 Oct;8(38):iii-iv, 1-196. Review.


Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit.

Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR.

Ann Intern Med. 2005 Aug 16;143(4):241-50.


Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis.

Warkentin AE, Donadini MP, Spencer FA, Lim W, Crowther M.

J Thromb Haemost. 2012 Apr;10(4):512-20. doi: 10.1111/j.1538-7836.2012.04635.x. Review.


Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.

Cohen M, Théroux P, Borzak S, Frey MJ, White HD, Van Mieghem W, Senatore F, Lis J, Mukherjee R, Harris K, Bigonzi F; ACUTE II Investigators.

Am Heart J. 2002 Sep;144(3):470-7.


Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study.

Jolly SS, Pogue J, Haladyn K, Peters RJ, Fox KA, Avezum A, Gersh BJ, Rupprecht HJ, Yusuf S, Mehta SR.

Eur Heart J. 2009 Apr;30(8):900-7. doi: 10.1093/eurheartj/ehn417. Epub 2008 Sep 26.


A high maintenance dose of clopidogrel improves short-term clinical outcomes in patients with acute coronary syndrome undergoing drug-eluting stent implantation.

Han YL, Wang B, Li Y, Xu K, Wang SL, Jing QM, Wang ZL, Wang DM, Ma YY, Wang G.

Chin Med J (Engl). 2009 Apr 5;122(7):793-7.


Characteristics, management and outcomes of patients with acute coronary syndrome and prior coronary artery bypass surgery: findings from the second Gulf Registry of Acute Coronary Events.

Al-Aqeedi R, Sulaiman K, Al Suwaidi J, Alhabib K, El-Menyar A, Panduranga P, Alshiekh-Ali A, Al Saif S.

Interact Cardiovasc Thorac Surg. 2011 Dec;13(6):611-8. doi: 10.1510/icvts.2011.274571. Epub 2011 Sep 13.


Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.

Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, Tijssen JG, Van de Werf F, Wallentin L; RE-DEEM Investigators.

Eur Heart J. 2011 Nov;32(22):2781-9. doi: 10.1093/eurheartj/ehr113. Epub 2011 May 7.


Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation.

Eshtehardi P, Windecker S, Cook S, Billinger M, Togni M, Garachemani A, Meier B, Hess OM, Wenaweser P.

Am Heart J. 2010 May;159(5):891-898.e1. doi: 10.1016/j.ahj.2010.02.025.


Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy.

Bonello L, De Labriolle A, Lemesle G, Steinberg DH, Roy P, Torguson R, Suddath WO, Satler LF, Kent KM, Pichard AD, Waksman R.

Catheter Cardiovasc Interv. 2009 Jun 1;73(7):866-70. doi: 10.1002/ccd.21935.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk